The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
"Diabodies": small bivalent and bispecific antibody fragments.
Open accessAbstract
Bivalent and bispecific antibodies and their fragments have immense potential for practical application. Here we describe the design of small antibody fragments with two antigen-binding sites. The fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) on the same polypeptide chain (VH-VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. As indicated by a computer graphic model of the dimers, the two pairs of domains can pack together with the antigen-binding sites pointing in opposite directions. The dimeric antibody fragments, or "diabodies," can be designed for bivalent or bispecific interactions. Starting from the monoclonal antibodies NQ11.7.22 (NQ11) and D1.3 directed against the hapten phenyloxazolone and hen egg lysozyme, respectively, we built bivalent fragments (VHNQ11-VLNQ11)2 and (VHD1.3-VLD1.3)2 and bispecific fragments VHNQ11-VLD1.3 and VHD1.3-VLNQ11. The fragments were expressed by secretion from bacteria and shown to bind specifically to the hapten and/or antigen. Those with 5- and 15-residue linkers had similar binding affinities to the parent antibodies, but a fragment with the VH domain joined directly to the VL domain was found to have slower dissociation kinetics and an improved affinity for hapten. Diabodies offer a ready means of constructing small bivalent and bispecific antibody fragments in bacteria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,423
Self-citationHuston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotný, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., & Crea, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.5879 · Cited by 1,593
Single-Chain Antigen-Binding Proteins
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S.-M., Lee, T., Pope, S. H., Riordan, G. S., & Whitlow, M. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,502
Munro, S., & Pelham, H. R. B. (1986) · Cell · doi:10.1016/0092-8674(86)90746-4 · Cited by 1,449
Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution
Amit, A. G., Mariuzza, R. A., Phillips, S. E. V., & Poljak, R. J. (1986) · Science · doi:10.1126/science.2426778 · Cited by 1,182
Hoogenboom, H. R., Griffiths, A. D., Johnson, K. S., Chiswell, D. J., Hudson, P., & Winter, G. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.15.4133 · Cited by 1,020
Self-citationWard, E. S., Güssow, D., Griffiths, A. D., Jones, P. T., & Winter, G. (1989) · Nature · doi:10.1038/341544a0 · Cited by 1,003
Self-citationAssembly of a Functional Immunoglobulin F v Fragment in Escherichia coli
Skerra, A., & Plückthun, A. (1988) · Science · doi:10.1126/science.3285470 · Cited by 978
Cited by
Engineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Self-citationMaking antibodies by phage display technology
Winter, G., Griffiths, A. D., Hawkins, R. E., & Hoogenboom, H. R. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002245 · Cited by 1,573
Self-citationTherapeutic antibodies: successes, limitations and hopes for the future
Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Isolation of high affinity human antibodies directly from large synthetic repertoires.
Griffiths, A. D., Williams, S. C., Hartley, O., Tomlinson, I. M., Waterhouse, P., Crosby, W. L., Kontermann, R. E., Jones, P. T., Low, N. M., & Allison, T. J. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06626.x · Cited by 962
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain
Nord, K., Gunneriusson, E., Ringdahl, J., Ståhl, S., Uhlén, M., & Nygren, P.-Å. (1997) · Nature Biotechnology · doi:10.1038/nbt0897-772 · Cited by 662
Schuck, P. (1997) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.26.1.541 · Cited by 657
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Antibody arrays for high-throughput screening of antibody–antigen interactions
de Wildt, R. M. T., Mundy, C. R., Gorick, B. D., & Tomlinson, I. M. (2000) · Nature Biotechnology · doi:10.1038/79494 · Cited by 624
Stability engineering of antibody single-chain Fv fragments
Wörn, A., & Plückthun, A. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4265 · Cited by 616
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Kontermann, R. E., & Brinkmann, U. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.008 · Cited by 578
Antibody fragments from a ‘single pot’ phage display library as immunochemical reagents.
Nissim, A., Hoogenboom, H. R., Tomlinson, I. M., Flynn, G., Midgley, C., Lane, D., & Winter, G. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06308.x · Cited by 574
Self-citationMammen, M., Choi, S.-K., & Whitesides, G. M. (1998) · Angewandte Chemie · doi:10.1002/(sici)1521-3757(19981016)110:20<2908::aid-ange2908>3.0.co;2-2 · Cited by 574
Single domain camel antibodies: current status
Muyldermans, S. (2001) · Reviews in Molecular Biotechnology · doi:10.1016/s1389-0352(01)00021-6 · Cited by 552
Therapeutic antibodies for human diseases at the dawn of the twenty-first century
Brekke, O. H., & Sandlie, I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd984 · Cited by 550
de Haard, H. J., van Neer, N., Reurs, A., Hufton, S. E., Roovers, R. C., Henderikx, P., de Bruı̈ne, A. P., Arends, J.-W., & Hoogenboom, H. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.26.18218 · Cited by 533
Antibody phage display technology and its applications
Hoogenboom, H. R., de Bruı̈ne, A. P., Hufton, S. E., Hoet, R. M., Arends, J.-W., & Roovers, R. C. (1998) · Immunotechnology · doi:10.1016/s1380-2933(98)00007-4 · Cited by 512
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Dual targeting strategies with bispecific antibodies
Kontermann, R. (2012) · mAbs · doi:10.4161/mabs.4.2.19000 · Cited by 435
Tau Aggregation and Its Interplay with Amyloid-β
Nisbet, R. M., Polanco, J.-C., Ittner, L. M., & Götz, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1371-2 · Cited by 359
“They can also be linked together to form bivalent or bispecific diabodies, which exhibit increased stability and binding or dual specificity, respectively [39] (Fig.”
BackgroundAntibodies and Genetically Engineered Related Molecules: Production and Purification
Roque, A. C. A., Lowe, C. R., & Taipa, M. A. (2004) · Biotechnology Progress · doi:10.1021/bp030070k · Cited by 360
Mack, M., Riethmüller, G., & Kufer, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7021 · Cited by 351
Phage display technology: clinical applications and recent innovations
Azzazy, H. M. E., & Highsmith, W. E. (2002) · Clinical Biochemistry · doi:10.1016/s0009-9120(02)00343-0 · Cited by 351
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336
“By reducing the length of the peptide linker between variable domains so that the domains cannot assemble, it is possible to force the pairing of domains from two different polypeptides, leading to compact bsAbs called diabodies (Dbs) [15].”
BackgroundAntibody‐Conjugated Nanoparticles for Biomedical Applications
Arruebo, M., Valladares, M., & González-Fernández, Á. (2009) · Journal of Nanomaterials · doi:10.1155/2009/439389 · Cited by 331
New protein engineering approaches to multivalent and bispecific antibody fragments
Plückthun, A., & Pack, P. (1997) · Immunotechnology · doi:10.1016/s1380-2933(97)00067-5 · Cited by 322
Exploiting recombination in single bacteria to make large phage antibody libraries
Sblattero, D., & Bradbury, A. (2000) · Nature Biotechnology · doi:10.1038/71958 · Cited by 316
Els Conrath, K., Lauwereys, M., Wyns, L., & Muyldermans, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007734200 · Cited by 300
Antibodies from phage antibody libraries
Bradbury, A. R. M., & Marks, J. D. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.04.007 · Cited by 296
Bispecific antibodies: design, therapy, perspectives
Sedykh, S., Prinz, V., Buneva, V., & Nevinsky, G. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s151282 · Cited by 292
Schouten, A., Roosien, J., van Engelen, F. A., (Ineke) de Jong, G. A. M., (Tanja) Borst-Vrenssen, A. W. M., Zilverentant, J. F., Bosch, D., Stiekema, W. J., Gommers, F. J., Schots, A., et al. (1996) · Plant Molecular Biology · doi:10.1007/bf00019011 · Cited by 290
Oligomer Formation By 3D Domain Swapping: A Model For Protein Assembly And Misassembly
SCHLUNEGGER, M., BENNETT, M., & EISENBERG, D. (1997) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60319-8 · Cited by 286
Current progress in innovative engineered antibodies
Strohl, W. R. (2018) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 279
Design and Production of Bispecific Antibodies
Wang, Q., Chen, Y., Park, J., Liu, X., Hu, Y., Wang, T., McFarland, K., & Betenbaugh, M. J. (2019) · Antibodies · doi:10.3390/antib8030043 · Cited by 279
Design and application of diabodies, triabodies and tetrabodies for cancer targeting
Todorovska, A., Roovers, R. C., Dolezal, O., Kortt, A. A., Hoogenboom, H. R., & Hudson, P. J. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00342-2 · Cited by 272
Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems
Verma, R., Boleti, E., & George, A. J. T. (1998) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00077-5 · Cited by 265
Applications of single-chain variable fragment antibodies in therapeutics and diagnostics
Weisser, N. E., & Hall, J. C. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2009.04.004 · Cited by 261
Novel immunotherapies in lymphoid malignancies
Batlevi, C. L., Matsuki, E., Brentjens, R. J., & Younes, A. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.187 · Cited by 260
David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments
Bates, A., & Power, C. A. (2019) · Antibodies · doi:10.3390/antib8020028 · Cited by 237
A revival of bispecific antibodies
Kufer, P., Lutterbüse, R., & Baeuerle, P. A. (2004) · Trends in Biotechnology · doi:10.1016/j.tibtech.2004.03.006 · Cited by 157
“In ‘diabodies’, each VL domain is connected by a short peptide linker with the VH domain of the other antigen specificity and vice versa [ 24 ].”
BackgroundTreatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody
Hartmann, F., Renner, C., Jung, W., Deisting, C., Juwana, M., Eichentopf, B., Kloft, M., & Pfreundschuh, M. (1997) · Blood · doi:10.1182/blood.v89.6.2042 · Cited by 149
Developments and Challenges for mAb-Based Therapeutics
Goswami, S., Wang, W., Arakawa, T., & Ohtake, S. (2013) · Antibodies · doi:10.3390/antib2030452 · Cited by 144
“In diabodies, each VL domain is connected by a short peptide linker to the VH domain of the other antigen specificity, and vice versa [248].”
BackgroundLe Gall, F., Kipriyanov, S. M., Moldenhauer, G., & Little, M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00713-9 · Cited by 128
KORTT, A. A., MALBY, R. L., CALDWELL, J. B., GRUEN, L. C., IVANCIC, N., LAWRENCE, M. C., HOWLETT, G. J., WEBSTER, R. G., HUDSON, P. J., & COLMAN, P. M. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.tb18724.x · Cited by 128
Triabodies: Single chain Fv fragments without a linker form trivalent trimers
Iliades, P., Kortt, A. A., & Hudson, P. J. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00475-4 · Cited by 110
Zhang, X., Yang, Y., Zhang, L., Lu, Y., Zhang, Q., Fan, D., Zhang, Y., Zhang, Y., Ye, Z., & Xiong, D. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0397-z · Cited by 89
“The concept of dimerizing scFv fragments having a short peptide linker between the domains to create two antigen-binding sites pointing in opposite directions [27] was extended to single-chain molecules containing four antibody variable domains [8].”
BackgroundAsano, R., Sone, Y., Makabe, K., Tsumoto, K., Hayashi, H., Katayose, Y., Unno, M., Kudo, T., & Kumagai, I. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0059 · Cited by 72
Grosse‐Hovest, L., Hartlapp, I., Marwan, W., Brem, G., Rammensee, H., & Jung, G. (2003) · European Journal of Immunology · doi:10.1002/eji.200323322 · Cited by 62
Orientation of antigen binding sites in dimeric and trimeric single chain Fv antibody fragments
Lawrence, L. J., Kortt, A. A., Iliades, P., Tulloch, P. A., & Hudson, P. J. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00292-0 · Cited by 50
In vitro affinity maturation of antibody against membrane-bound GPCR molecules
Wang, J., An, L., Zhao, Y., Zhang, C., Li, S., Ye, C., Jing, S., & Hang, H. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-10030-x · Cited by 11
“However, detergent solubilization often alters the functional conformation of a GPCR; thus, this method is not always possible to mature an antibody against a specific functional conformation (Geppetti et al. 2015; Hansen et al. 2018; Hotzel et al. 2011).”
Background
Metadata
- Authors
- Holliger, P., Prospero, T., & Winter, G.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1993-07-15
- Volume
- 90
- Issue
- 14
- Pages
- 6444-6448
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1996820981
- Cited by
- 874
- References
- 32
- FWCI
- 25.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.